266 related articles for article (PubMed ID: 2582446)
1. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
2. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
3. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
4. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
5. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Camplyobacter jejuni.
Ritter G; Fortunato SR; Cohen L; Noguchi Y; Bernard EM; Stockert E; Old LJ
Int J Cancer; 1996 Apr; 66(2):184-90. PubMed ID: 8603809
[TBL] [Abstract][Full Text] [Related]
6. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
7. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
8. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
[TBL] [Abstract][Full Text] [Related]
10. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
11. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity.
Natoli EJ; Livingston PO; Pukel CS; Lloyd KO; Wiegandt H; Szalay J; Oettgen HF; Old LJ
Cancer Res; 1986 Aug; 46(8):4116-20. PubMed ID: 3731079
[TBL] [Abstract][Full Text] [Related]
12. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
[TBL] [Abstract][Full Text] [Related]
13. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse.
Ritter G; Boosfeld E; Calves MJ; Oettgen HF; Old LJ; Livingston PO
Immunobiology; 1990 Dec; 182(1):32-43. PubMed ID: 2098322
[TBL] [Abstract][Full Text] [Related]
15. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
Livingston PO; Wong GY; Adluri S; Tao Y; Padavan M; Parente R; Hanlon C; Calves MJ; Helling F; Ritter G
J Clin Oncol; 1994 May; 12(5):1036-44. PubMed ID: 8164027
[TBL] [Abstract][Full Text] [Related]
17. Gangliosides elicit a T-cell independent antibody response.
Freimer ML; McIntosh K; Adams RA; Alving CR; Drachman DB
J Autoimmun; 1993 Jun; 6(3):281-9. PubMed ID: 8397712
[TBL] [Abstract][Full Text] [Related]
18. Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers.
Hirabayashi Y; Kasakura H; Matsumoto M; Higashi H; Kato S; Kasai N; Naiki M
Jpn J Cancer Res; 1987 Mar; 78(3):251-60. PubMed ID: 3106281
[TBL] [Abstract][Full Text] [Related]
19. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
20. Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient.
Abdel-wahab ZA; Gillanders WE; Darrow TL; Seigler HF
Hum Antibodies Hybridomas; 1992 Jan; 3(1):32-9. PubMed ID: 1576321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
